Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


184 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

NXS, NEXT SCIENCE LIMITED
nipper
post Posted: Dec 21 2019, 12:28 PM
  Quote Post


Posts: 7,619
Thanks: 2565


In Reply To: nipper's post @ Dec 20 2019, 01:35 PM

and, ...
QUOTE
All the research and development comes at a serious cost though, and for the nine months ending September 30 it posted an operating cash loss of $US9.1 million ($13.2 million) on sales of just $US2.86 million. The balance sheet is in reasonable shape with $US20.3 million cash on hand as at September 30.

... it normally partners with third parties to distribute its products, as that allows it to access global networks without the heavy sales and marketing costs....

Next Science is forecasting cash outflows before sales of US$5.07 million for the December quarter and is due to hand in its first full-year report as a public company in February




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 20 2019, 01:35 PM
  Quote Post


Posts: 7,619
Thanks: 2565


In Reply To: nipper's post @ Dec 20 2019, 12:08 PM

QUOTE
Next Science climbed 6 per cent ...
... yes, but that was to $1.84. It was $4 in July.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 20 2019, 12:08 PM
  Quote Post


Posts: 7,619
Thanks: 2565


QUOTE
Next Science climbed 6 per cent on Thursday after it revealed a five-year deal to have its TorrentX Wash Wound product distributed in the US by Tennessee-based Triad Life Sciences.

Founded in 2012 Next Science has patented medical technology named Xbio that attacks and kills bacterial surfaces known as biofilms.

The group's products are generally used as a topical application by surgeons or medical professionals to treat or wash patients' wounds in the operating theatre or on a post-operative basis. The aim is to prevent unwanted bacterial infections common to hospitals such as MRSA (Golden Staph) and E.coli or Staphylococcus.

Including TorrentX Wash Wound, the company has four products approved for commercial sale in the lucrative US healthcare market. Most of its sales currently come from its BlastX surgical wash and Bactisure wound gel. It expects to have another four products approved in the US or Europe over the course of 2020. These include washes or disinfectants for sinusitis, chronic ear infections, or general surgical procedures




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 27 2019, 02:51 PM
  Quote Post


Posts: 7,619
Thanks: 2565


Now $3.60, up 30% today on Investor Presentation

- the idea of 80% margin is attractive if patents hold and a competitor doesn't emerge.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 14 2019, 06:18 PM
  Quote Post


Posts: 7,619
Thanks: 2565


QUOTE
Medical technology is about as far as you can get from property development but that has not stopped billionaire Lang Walker finding and backing one of the most promising medical technology stocks listed on the ASX. According to Next Science chief executive Judith Mitchell it was luck and serendipity that resulted in Walker getting the opportunity to be the first significant backer of a company with technology that's had extraordinary early success.

Next Science, which is 42 per cent owned by Walker, has risen from a first day's trading closing price of $1.35 a share to $2.13 on Tuesday. The company raised $35 million at $1 a share but the smart money, including Regal Funds Management, got in early at 80¢ a share before the IPO.

Florida-based American doctor Matthew Myntti was looking for expansion capital after he invented a new method for attacking superbugs that lurk in hospitals and affect people with chronic wounds. The patented Xbio technology used in various medical devices has been proven to eradicate the biofilm that forms a shield around bacteria resistant to traditional forms of eradication such as antibiotics. About 90 per cent of bacteria is referred to as biofilm bacteria.

Mitchell says the sister-in-law of Myntti’s sister-in-law drew the invention to the attention of a researcher working for Walker’s investment arm, which is run by former deal maker Bruce Hancox.
https://www.afr.com/chanticleer/billionaire...20190514-p51n2q



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 8 2019, 03:56 PM
  Quote Post


Posts: 7,619
Thanks: 2565


QUOTE
Next Science Ltd (NXS : ASX)
– Global chronic wound care biotech

Next Science is a biotech company focused on infection control. It is the patent holder and developer of a unique non-toxic technology designed to eradicate biofilm based bacteria.

A biofilm is like a bomb shelter for bacteria and tends to be present in chronic wounds that prove resistant to healing. These wounds affect 11.6 million people in US, UK, Germany and Australia annually and they have a treatment cost of $9 billion a year.

Next Science’s core technology has been tested extensively in US hospitals and are proven to be up to 1000 times more effective than the next best treatment available.

The company has 4 products that are U.S. Food and Drug Administration registered that will likely generate revenue in FY19 and FY20.

The company listed at on the Australian Securities Exchange at $1 last month and is now trading at $1.70, giving it a market cap of about $300 million.

Conservative estimates of penetration into wound care markets globally over the medium term would suggest the company has significant earnings growth potential in the coming years.
IFM Investors, small cap pick

..... now $2.30



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

Featured Stock Stories





nipper
post Posted: Apr 24 2019, 03:04 PM
  Quote Post


Posts: 7,619
Thanks: 2565


Out of the ashes
Next Science Ltd - code NXS
QUOTE
Commercialising and developing its Xbio technology, which is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria, in a range of products for the treatment of biofilm based infections.

... 35 mill shares issued @ $1.00 ; but a whole lot more out there. ....has risen to $1.70 over the last few days since the chopshop rebirth.
- "tightly held"
QUOTE
The Company’s technology is currently protected by 15 patents and 47 patent applications throughout the world. The Company’s proprietary Xbio technology is a non-toxic technology which is used in eradicating biofilm and biofilm-protected bacteria. This technology has been validated by extensive clinical testing, multiple FDA clearances and more than 70,000 patient treatments since 2017. Xbio technology is being sold in the US market to eliminate biofilm-protected bacteria in surgery and chronic wound care applications.

The proceeds from the Offer will be used to expand the company’s product development activities, for administration costs and working capital, and to pay for the costs of the Offer. The company is planning to launch four more Xbio-based products by the end of CY 2019.

The company is having distribution agreements with major multinationals 3M and Zimmer Biomet and has a pipeline of additional product development opportunities planned for the short and medium term. The company is expecting the sales of its acne treatment to start in Australia in the second half of 2019 under an agreement with Advanced Skin Technology.

Next Science’s business model is to further develop and commercialize its proprietary Xbio technology in a range of products for the treatment of biofilm-based infections. The Company generates revenues by offering its products for sale primarily through distribution partnerships with major health companies. The distribution through the third party provides Next Science with access to large global markets without incurring extensive sales and marketing expenditures. This allows Next Science to grow while maintaining a focus on ongoing research and development activities aimed at unlocking further healthcare products and market opportunities for its patented Xbio technology. Next Science intends to continue its strategy of sales through established distributors rather than directly market and sell its products itself...




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
JAG
post Posted: Sep 24 2015, 10:16 AM
  Quote Post


Posts: 64
Thanks: 2


Is anyone aware of how we can get a final transaction statement for those who held shares in Nexes Energy (NXS)at the final bell.

My Accountant wants to complete end of year figures and I cannot locate any data.

Any advice appreciated.

Thanks

Jag




 
triage
post Posted: Jun 13 2014, 11:43 AM
  Quote Post


Posts: 3,862
Thanks: 1557


In Reply To: PeterH's post @ Jun 13 2014, 10:50 AM

I have had a couple of goes at NXS over the years but got out the last time when Richard Cottee departed. For a company with such promising assets it really is a shame to see it dragged into the mud like this so condolences to those who have lost on this one. I don't know but clearly there is a widely held suspicion that the main cause for this travesty is at the board level (??).

I see the shareholders association rep called it crazy-brave by retail holders to vote against Kerry Stokes and Don Voelte having an easy win. But my impression is that for many it was quite a wilful reasoned move. No doubt some were hoping for a white knight to appear and save them from losing all their dough but I thought other factors are in play. One I think is the hope that the administrators may look into how the board, perhaps diliberately or negligently, made a series of decisions that ended up handing Mr Stokes some great assets for bugger all. Another factor I thought was the prospect that by deciding to let the company go into administration they would trigger the pre-emptive rights of the joint venturers in the Longtom and WA assets, not so much so that those assets would be liquidated at a higher return for shareholders than that being offered by Kerry Stokes but more so that Mr Stokes does not get those assets fullstop.

Anyway I reckon it was a brave stand by current holders and hopefully it was not for naught.



--------------------
"The market can stay irrational longer than you can stay solvent." John Maynard Keynes

"The crisis takes a much longer time coming than you think, and then it happens much faster than you would have thought." Rudiger Dornbush

Mozart fixes everything and Messi is a dog
 
PeterH
post Posted: Jun 13 2014, 10:50 AM
  Quote Post


Posts: 546
Thanks: 110


In Reply To: fraz2's post @ Jun 12 2014, 09:06 PM

SGH will get the company for nothing because, as its creditor, it will exchange proprietorship for debt obligation. Under those circumstances there will be no other bidder - probably there cannot be and SGH know that.

I sold my painful holding for .019 the other day when I realised the window would be open only momentarily. Good luck to anyone who can does better.

I hesitate to name the high profile market commentator who tipped this one and was, without doubt, the deciding factor in making me buy it in the first place. He said that Nexus was going to be the next Woodside and for a while that looked possible. He is still a good bloke and we can all make mistakes, but now I ignore his tips.

This has brought home to me again, and finally, I hope, that old lesson that we should never buy on tips. For sure tips have cost me a lot more than they have gained.

 
 


184 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING